Loading stock…

Illumina, Inc. (ILMN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Illumina, Inc.

ILMNMarket cap $41BPrice $273.5

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes the DNA sequencing machines that power most of the world's genetic research, from cancer diagnostics to ancestry tests. Roughly 80% of all sequencing data globally runs through Illumina's technology, making it the backbone of modern genomics.

In Bastion Portfolios?

52W Return+187%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-2%2

Revenue Forecast

Rev CAGR (1y)+6%5

Rev CAGR (3y)+7%5

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1-0%3

EPS Growth Y+2+15%7

EPS Growth Y+3+14%7

Quality

Margins

EBIT Margin20%7

Net Income Margin18%8

Free Cash Flow Margin21%8

Debt

Net Debt/EBITDA1.16

Efficiency

ROE32%9

ROA13%9

Earnings Stability22

GEAR+AVERAGE35

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)511

P/E Ratio (Forward 3y)381

P/BV13.61

EV Multiples

EV/EBITDA Fwd351

EV/EBIT Fwd421

Yield

Free Cash Flow Yield2.4%4

Dividend Yieldna–

Momentum

Short term

1 month return+25%10

3 month return+43%10

YTD return+109%10

Mid term

Price vs 52wHigh88%7

1 year return+183%10

Long term

3 year return+101%7

5 year return-30%2

Risk Shield

Price Risk

Beta1.13

Volatility48%3

Free Cash Flow

Free Cash Flow Margin21%8

Free Cash Flow Yield2.4%4

Quality

ROCE18%8

Earnings Stability22

Net Debt/EBITDA1.16

02Growth

Is it actually growing, and how fast?

ILMNIllumina

Revenue FY25$4.3B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-0%3

EPS growth, FY27E+15%7

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 7%/yr from here.

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 7%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG84 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+25%10

3-month return+43%10

YTD return+109%10

MID & LONG-TERM▾SCORE

% of 52-week high88%7

1-year return+183%10

3-year return+101%7

5-year return-30%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 183% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+25%), over three months (+43%) and so far this year (+109%).

WATCH

Average long-term results. Multi-year returns are middling (+101% over three years and -30% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Illumina, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ILMNIllumina

Revenue FY25$4.3B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-0%3

EPS growth, FY27E+15%7

EPS growth, FY28E+14%7

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 7%/yr from here.

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 7%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG84 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+25%10

3-month return+43%10

YTD return+109%10

MID & LONG-TERM▾SCORE

% of 52-week high88%7

1-year return+183%10

3-year return+101%7

5-year return-30%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 183% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+25%), over three months (+43%) and so far this year (+109%).

WATCH

Average long-term results. Multi-year returns are middling (+101% over three years and -30% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Illumina, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community